🎙️ Episode 26: Radiation Optional? Rethinking Esophageal Cancer Pre-Op

🧪 The EPOC Trial:

Compared FLOT chemotherapy alone vs chemo + radiation before surgery in localized esophageal/gastroesophageal adenocarcinoma.

📈 Findings:

FLOT alone led to better 3-year progression-free survival: 51.6% vs 35%.

No survival benefit from adding radiation.

Patients receiving FLOT alone had fewer complications, improved tolerance, and less treatment-related morbidity.

🧩 Clinical Takeaway:

For operable esophageal adenocarcinoma, skip the radiation if you're doing full-dose chemo.

Less burden for patients, especially elderly or frail.

Transcript

Intro to Preoperative Treatment Study

Speaker 1 0:01

Now let's talk about preoperative chemoradiotherapy for resectable esophageal carcinoma . So adding radiation therapy in the preoperative treatment of gastroesophageal adenocarcinoma resulted in no survival benefit over chemotherapy alone . Why is this important ? Well , just think about , if you're a patient , first of all , the side effects of gut irradiation , but also , is your life going well when you have esophageal

Patient Quality of Life Concerns

Speaker 1 0:28

carcinoma ? You're probably not going to be eating well , you're probably not getting great nutrition , and just think you have to get somebody to drive you to get this radiation therapy . You have to be able to get the radiation therapy . You've seen patients who've undergone radiation therapy . Is their life great at that moment ? No , it sucks . So this is an opportunity to reduce pain and suffering for patients .

Speaker 1 0:54

So this is in patients , the ESOPEC trial , we'll call it that Patients with esophageal or gasoesophageal junction endocarcinoma . So they had

ESOPEC Trial Results & Significance

Speaker 1 1:04

two arms one where they see float chemotherapy , which is fluoruracil , lucavorn , oxaliplatin or dosotaxel part of the float chemotherapy , or perioperative chemoradiotherapy with carboplatin , paxitaxel and radiotherapy . Now what they measured is a progression-free survival of three years with flow was superior to chemo radiotherapy with no new safety signals , and the progression-free survival was pretty significant . The flow compared to the chemo radiotherapy was 51.6% to 35% progression-free survival

Progression-Free Survival Data

Speaker 1 1:50

of three years and the pathological . The tissue response was 12.7% versus 10.1% . So big breakthrough for resectable esophageal carcinoma in the perioperative and preoperative treatment levels .